Biotron Limited (BITRF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -3.43 Million AUD | 1.61% |
| 2023 | -3.49 Million AUD | -25.59% |
| 2022 | -2.78 Million AUD | 12.94% |
| 2021 | -3.19 Million AUD | 10.67% |
| 2020 | -3.57 Million AUD | -121.86% |
| 2019 | -1.61 Million AUD | -1.14% |
| 2018 | -1.59 Million AUD | 48.48% |
| 2017 | -3.09 Million AUD | -2.97% |
| 2016 | -3 Million AUD | -10.32% |
| 2015 | -2.72 Million AUD | 11.75% |
| 2014 | -3.08 Million AUD | 19.86% |
| 2013 | -3.85 Million AUD | -61.93% |
| 2012 | -2.37 Million AUD | -24.67% |
| 2011 | -1.9 Million AUD | -1.88% |
| 2010 | -1.87 Million AUD | -5.41% |
| 2009 | -1.77 Million AUD | 5.63% |
| 2008 | -1.88 Million AUD | 41.8% |
| 2007 | -3.23 Million AUD | -47.07% |
| 2006 | -2.19 Million AUD | -16.74% |
| 2005 | -1.88 Million AUD | 0.0% |
| 2004 | - AUD | 100.0% |
| 2003 | -2.72 Million AUD | -63.69% |
| 2002 | -1.66 Million AUD | -30.23% |
| 2001 | -1.28 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -1.05 Million AUD | 20.2% |
| 2024 Q4 | -1.05 Million AUD | 0.0% |
| 2024 FY | -3.43 Million AUD | 1.61% |
| 2024 Q1 | -661.9 Thousand AUD | 75.48% |
| 2024 Q2 | -1.32 Million AUD | -100.0% |
| 2023 FY | -3.49 Million AUD | -25.59% |
| 2023 Q2 | -793.58 Thousand AUD | -100.0% |
| 2023 Q1 | -396.79 Thousand AUD | 52.89% |
| 2023 Q3 | -1.34 Million AUD | -70.06% |
| 2023 Q4 | -2.69 Million AUD | -100.0% |
| 2022 Q4 | -842.22 Thousand AUD | -100.0% |
| 2022 Q3 | -421.11 Thousand AUD | 78.28% |
| 2022 FY | -2.78 Million AUD | 12.94% |
| 2022 Q1 | -969.43 Thousand AUD | -21.82% |
| 2022 Q2 | -1.93 Million AUD | -100.0% |
| 2021 Q3 | -397.89 Thousand AUD | 83.41% |
| 2021 Q1 | -1.19 Million AUD | 20.24% |
| 2021 Q4 | -795.79 Thousand AUD | -100.0% |
| 2021 FY | -3.19 Million AUD | 10.67% |
| 2021 Q2 | -2.39 Million AUD | -100.0% |
| 2020 Q2 | -2.07 Million AUD | -100.0% |
| 2020 Q4 | -1.5 Million AUD | -100.0% |
| 2020 FY | -3.57 Million AUD | -121.86% |
| 2020 Q1 | -1.03 Million AUD | 23.28% |
| 2020 Q3 | -751.78 Thousand AUD | 63.72% |
| 2019 FY | -1.61 Million AUD | -1.14% |
| 2019 Q4 | -1.35 Million AUD | -100.0% |
| 2019 Q3 | -675.33 Thousand AUD | -417.24% |
| 2019 Q2 | -130.56 Thousand AUD | 0.0% |
| 2019 Q1 | -130.56 Thousand AUD | 81.79% |
| 2018 Q1 | -79.9 Thousand AUD | 85.24% |
| 2018 FY | -1.59 Million AUD | 48.48% |
| 2018 Q4 | -716.92 Thousand AUD | 0.0% |
| 2018 Q3 | -716.92 Thousand AUD | -797.29% |
| 2018 Q2 | -79.89 Thousand AUD | 0.0% |
| 2017 FY | -3.09 Million AUD | -2.97% |
| 2017 Q4 | -541.3 Thousand AUD | 0.0% |
| 2017 Q3 | -541.3 Thousand AUD | 46.16% |
| 2017 Q1 | -1 Million AUD | -762.96% |
| 2017 Q2 | -1 Million AUD | 0.0% |
| 2016 Q4 | -116.5 Thousand AUD | 0.0% |
| 2016 Q2 | -1.38 Million AUD | 0.0% |
| 2016 Q1 | -1.38 Million AUD | -412.17% |
| 2016 FY | -3 Million AUD | -10.32% |
| 2016 Q3 | -116.5 Thousand AUD | 91.59% |
| 2015 Q4 | -270.54 Thousand AUD | 0.0% |
| 2015 Q3 | -270.54 Thousand AUD | 75.2% |
| 2015 FY | -2.72 Million AUD | 11.75% |
| 2015 Q2 | -1.09 Million AUD | 0.0% |
| 2015 Q1 | -1.09 Million AUD | -358.46% |
| 2014 FY | -3.08 Million AUD | 19.86% |
| 2014 Q3 | -237.98 Thousand AUD | 81.76% |
| 2014 Q2 | -1.3 Million AUD | 0.0% |
| 2014 Q1 | -1.3 Million AUD | -71.11% |
| 2014 Q4 | -237.98 Thousand AUD | 0.0% |
| 2013 FY | -3.85 Million AUD | -61.93% |
| 2013 Q3 | -762.63 Thousand AUD | 0.0% |
| 2013 Q4 | -762.63 Thousand AUD | 0.0% |
| 2012 FY | -2.37 Million AUD | -24.67% |
| 2011 FY | -1.9 Million AUD | -1.88% |
| 2010 FY | -1.87 Million AUD | -5.41% |
| 2009 FY | -1.77 Million AUD | 5.63% |
| 2008 FY | -1.88 Million AUD | 41.8% |
| 2007 FY | -3.23 Million AUD | -47.07% |
| 2006 FY | -2.19 Million AUD | -16.74% |
| 2005 FY | -1.88 Million AUD | 0.0% |
| 2004 FY | - AUD | 100.0% |
| 2003 FY | -2.72 Million AUD | -63.69% |
| 2002 FY | -1.66 Million AUD | -30.23% |
| 2001 FY | -1.28 Million AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -3.81 Million USD | 10.015% |
| Skye Bioscience, Inc. | -37.64 Million USD | 90.871% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 105.276% |
| Nascent Biotech, Inc. | -2.08 Million USD | -64.61% |
| Qrons Inc. | -789.34 Thousand USD | -335.363% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 59.489% |
| CSL Limited | 2.64 Billion USD | 100.13% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 106.487% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 50.786% |
| Regen BioPharma, Inc. | 1.02 Million USD | 435.759% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 94.51% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -727.123% |
| Rebus Holdings, Inc. | -1.02 Million USD | -236.914% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -157.334% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -443.404% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 78.348% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 95.416% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 47.742% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1156.949% |
| SQZ Biotechnologies Company | -79.46 Million USD | 95.675% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -18.812% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -88.765% |
| Mesoblast Limited | -87.95 Million USD | 96.093% |
| Marizyme, Inc. | -65.34 Million USD | 94.741% |
| Genus plc | 7.9 Million USD | 143.5% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 68.448% |
| Pharming Group N.V. | -10.54 Million USD | 67.42% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -58.379% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 7.377% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 61.143% |
| ContraFect Corporation | -65.15 Million USD | 94.725% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 29.667% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -98.936% |
| IMV Inc. | -36.48 Million USD | 90.581% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 57.362% |
| MultiCell Technologies, Inc. | -380.07 USD | -904081.861% |
| ONE Bio Corp. | 8.67 Million USD | 139.607% |
| Accustem Sciences Inc. | -3.74 Million USD | 8.272% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 93.352% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -171.204% |
| Q BioMed Inc. | -2.05 Million USD | -67.464% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 7.942% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -44.339% |
| Biomind Labs Inc. | -1.21 Million USD | -183.0% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 94.246% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -10.792% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 56.517% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -76.3% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -22846.875% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 40.925% |
| GB Sciences, Inc. | -1.36 Million USD | -152.374% |
| Alpha Cognition Inc. | -13.77 Million USD | 75.048% |
| HST Global, Inc. | -146.21 Thousand USD | -2250.403% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -95.839% |
| Halberd Corporation | -79.67 Thousand USD | -4213.123% |
| Enzolytics Inc. | -2.17 Million USD | -57.868% |
| Agentix Corp. | -1.37 Million USD | -150.073% |
| Resverlogix Corp. | -3.61 Million USD | 4.805% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -8.359% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.835% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3606.657% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 149.628% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 13.503% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -13.561% |
| AVAX Technologies, Inc. | -6.41 Million USD | 46.419% |
| Zenith Capital Corp. | -10.59 Million USD | 67.568% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.401% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -14685.836% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 17.111% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -5585.786% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -71.388% |
| Kadimastem Ltd | -3.3 Million USD | -3.904% |
| Helix BioMedix, Inc. | -1.05 Million USD | -225.411% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -678.606% |
| LadRx Corporation | 400.44 Thousand USD | 958.181% |
| Cell Source, Inc. | -5.32 Million USD | 35.418% |
| Regen BioPharma, Inc. | 1.02 Million USD | 435.759% |
| NovAccess Global Inc. | -4.76 Million USD | 27.943% |
| Affymax, Inc. | -14.42 Million USD | 76.175% |
| Itoco Inc. | -1.86 Million USD | -83.87% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 22.645% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -105.903% |
| Mobile Lads Corp. | -2.26 Million USD | -51.837% |
| CytoDyn Inc. | -49.84 Million USD | 93.105% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -4248.214% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1406.408% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -264.994% |
| SYBLEU INC | -180.3 Thousand USD | -1805.961% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -113.086% |
| International Stem Cell Corporation | -131 Thousand USD | -2523.301% |
| Bioxytran, Inc. | -4.28 Million USD | 19.707% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -6232.039% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -35.818% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 92.851% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -62.56% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -340.08% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -8.476% |
| Neutra Corp. | -233.46 Thousand USD | -1371.965% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 83.064% |
| PureTech Health plc | -65.69 Million USD | 94.769% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 83.841% |
| IXICO plc | -1.17 Million USD | -191.725% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 65.382% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 93.985% |
| CSL Limited | 2.64 Billion USD | 100.13% |
| Cellectis S.A. | -103.17 Million USD | 96.669% |